Research programme: Nanobodies - Ablynx/Merck Serono

Drug Profile

Research programme: Nanobodies - Ablynx/Merck Serono

Alternative Names: ALX 1141; ALX-0751

Latest Information Update: 05 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ablynx
  • Developer Ablynx; Merck Serono
  • Class Anti-inflammatories; Antineoplastics; Proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Osteoarthritis
  • Research Neurological disorders
  • No development reported Cancer; Immunological disorders; Inflammation

Most Recent Events

  • 24 Aug 2017 Merck plans a phase I trial for ALX 1141 for Osteoarthritis in second half of 2017
  • 05 Jun 2017 Preclinical trials in Osteoarthritis in Belgium (Parenteral) before June 2017 (Ablynx pipeline, June 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Belgium (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top